ARTICLE | Clinical News
PH80: Phase II data
January 1, 2007 8:00 AM UTC
In a double-blind, placebo-controlled Phase II trial in 56 evaluable women, 800 ng of intranasal PH80 given up to 4 times daily for 6 days met the primary endpoint of a significant improvement in PMS ...